Lead Product(s) : Empagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to discharge compared with placebo in the phase III EMPULSE trial...
Product Name : Jardiance
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : Empagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable